Important Safety Information
†Caution - LungFit is an Investigational Device, Limited by Federal (or United States) Law to Investigational Use.
Designed for Convenience
Benefitting Hospitals and Patients
Beyond Air’s Nitric Oxide (NO) generator and delivery system (LungFit) is capable of generating nitric oxide from ambient air to a patient’s lungs. This can be done continuously or for a fixed amount of time, with the capability to titrate dose on demand or maintain a constant dose.
For persistent pulmonary hypertension of the newborn (PPHN), our novel Beyond Air NO Delivery System (LungFit PH) is designed to deliver a dosage of nitric oxide to the lungs that is consistent with current guidelines for delivery of 20 ppm with a range of 0.5 – 80 ppm.
Demonstrated Safety Record
Safely delivering high concentration nitric oxide for lung infections
The Beyond Air Nitric Oxide Delivery System has a demonstrated safety record at a concentration of 250 ppm.
2,100+
treatments administered
85+
patients
8
different clinical settings
0
serious adverse events (SAEs) related to NO
Novel Delivery System
Beyond Air’s NO delivery system uses NO generated from ambient air with an innovative generator. It is designed to provide patients with a precise gaseous dose of NO (ranging from 1–400 ppm) combined with ambient air. The blend is supplied through a ventilator for concentrations up to 80 ppm and a face mask for concentrations of 160 ppm and higher.
Our product candidates resemble other inhalation systems, making them user friendly, with operation and maintenance we believe will be familiar to medical staff.
Our technology has the following features:
- Optimized to deliver 160 ppm and higher of constant flow nitric oxide
- Programmable and differentiated dosage regimens
- Elimination of high-pressure cylinders
- Constant NO concentration with variable ventilator flow
- Convenient and portable for patient use
- Non-invasive administration through a face mask
Markets
Competitive Advantages in Worldwide Markets
We believe our system has many competitive advantages over the current approved delivery systems in the U.S., European Union, Japan and other markets. For example, our system does not require a high-pressure cylinder and uses less space than similar devices. This means our technology can eliminate cumbersome purging procedures and lessen the burden on hospital staff of carrying out safety procedures.
Pipeline
Our Pipeline of Products Address Unmet Needs
We are advancing a promising pipeline of product candidates with an initial focus on treating PPHN, bronchiolitis and nontuberculous mycobacteria.
View Our Pipeline